News

New Combination Respiratory Therapy for COPD Approved by FDA

A new double-combination therapy that promotes lung expansion and airway clearance has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with lung diseases including chronic obstructive pulmonary disease (COPD) and asthma. The therapy was developed by the Monaghan Medical Corporation  and combines two…

COPD Triple-combination Therapy Approved in China, AstraZeneca Announces

AstraZeneca’s triple-combination therapy for people with chronic obstructive pulmonary disease (COPD) has been approved in China as a maintenance treatment. The therapy comprises three compounds: the corticosteroid budesonide, and two long-acting bronchodilators — glycopyrronium, a muscarinic antagonist, and formoterol fumarate, a β2-agonist. This combo…

Expanded Diagnostic Criteria Needed for COPD, Study Suggests

The criteria used to diagnose chronic obstructive pulmonary disease (COPD) should be expanded beyond measurements of lung function, a new study suggests. The study, “COPDGene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease,” was published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD…